Rheinmetall's Baltic Billet and a Bruised Tape: Why New Orders Aren't Moving the Needle

Rheinmetall's order book grows with a €250M Lithuania deal, but shares fall 28% YTD amid quality concerns and guidance cuts.

The defence contractor's order book keeps swelling, yet its share price tells a far more sobering story. The latest example arrived with the Bundeswehr's first call-off under the "G-CAP II SU" framework agreement, tasking Rheinmetall with building and operating a modular military installation in Lithuania. Construction work is worth €250 million, with an additional €40 million flowing in annually once the facility is operational.

That headline figure, however, is doing little to arrest a slide that has now erased 28 percent of the company's market value since the start of the year. The stock was changing hands at €1,117.00 on the day of the announcement, down 0.8 percent, extending the weekly loss to 7.8 percent. Even the more flattering monthly picture — a 5.4 percent gain — offers cold comfort against a 44 percent drawdown from the €2,007.00 52-week high touched on 3 October 2025.

A widening gap between operations and valuation

The disconnect between corporate headlines and market behaviour has become the defining feature of Rheinmetall's 2026. Just days before the Lithuanian contract surfaced, subsidiary Rheinmetall Project Solutions had secured an order worth more than €500 million for 149 additional protected and unprotected mobile medical stations, with production slated to begin in the first quarter of 2027. That followed a live demonstration of the FV-014 loitering munition system launching from the company's own containerised missile launcher mounted on an HX truck, and a joint exercise with Hensoldt at the Timber Express 2026 air force drill in Manching showcasing passive sensor integration into a modern air defence architecture.

The technological cadence is unmistakable. The share price response has been anything but. Rheinmetall closed Monday at €1,125.80 after a 2.8 percent daily decline, and the stock has shed roughly 2.9 percent since the second-quarter results landed just over three weeks ago. Investors, it seems, are increasingly discounting individual product milestones in favour of broader concerns about operational reliability and forecast credibility.

Quality concerns and a maritime setback

Part of that caution stems from media reports circulating about alleged quality deficiencies in the company's protective plates. Berlin prohibited the use of certain plates roughly a month ago, and the stock has lost about 3.1 percent since. The fresh speculation has also dragged on sector peers, with Hensoldt and Renk feeling the pressure alongside Rheinmetall.

Then there is the F126 frigate programme. The loss of that naval contract prompted Rheinmetall to cut its 2026 revenue guidance and triggered an unusually blunt response from chief executive Armin Papperger, who described himself as "very dissatisfied" with the outcome. The episode continues to colour analyst thinking about the company's medium-term trajectory.

Analysts split down the middle

The sell-side community remains sharply divided on valuation. RBC Capital Markets initiated coverage on 11 August with an "Outperform" rating and a €1,600 price target, with analyst Colin Moody projecting 35 percent annual EBITA growth through 2030. Goldman Sachs reaffirmed its buy recommendation on 15 August with a more ambitious €2,300 target, citing strong second-quarter results. Jefferies raised its price target from €1,300 to €1,350 on 14 August while keeping a "Buy" stance.

JPMorgan's David Perry, by contrast, holds at "Neutral" with a €1,350 target, pointing to uncertainty in revenue forecasts for the 2027–2030 period. The resulting target range — from €1,350 to €2,300 — captures the market's indecision about how to weigh a robust order pipeline against a guidance cut and a high-profile programme loss.

The numbers behind the narrative

The second-quarter figures themselves present a mixed picture. Revenue climbed 35.35 percent to €3.29 billion, yet earnings per share slipped from €2.90 to €2.66. Since those results were published, the shares have given back 2.9 percent. The next quarterly update arrives on 5 November, and it will likely show whether the Lithuanian contract and the medical stations expansion can offset the drag from the F126 disappointment on the full-year outlook.

For now, the market's attention turns to the DZ Bank expert day on the investor relations calendar, where analysts will be looking for evidence that the growth story can withstand the scrutiny of a sceptical shareholder base. The gap between the company's operational momentum and its share price performance suggests that bridge remains a long one.